Posted by Michael Wonder on 13 Jul 2021
Tecentriq, Kesimpta lead latest SMC decisions
13 July 2021 - The SMC has accepted three new medicines for use by NHS Scotland and rejected one in its July 2021 decisions.
The SMC also announced that it was unable to accept Pfizer’s Vyndaqel (tafamidis) for the treatment of the rare heart condition transthyretin amyloidosis.
